CRISPR-Cas13b mediated gene knockdowns in Leishmania infantum

Area of Science:

• Molecular Biology
• Parasitology
• Genetics

Background:

• Current Leishmania treatments are limited by cost and toxicity.
• Genomic approaches have advanced understanding of drug targets but lack knockdown systems.
• A functional knockdown system is crucial for Leishmania research.

Purpose of the Study:

• To establish and validate a CRISPR-Cas13 system for gene knockdown in Leishmania.
• To assess the system's efficacy on both exogenous and endogenous gene expression.
• To investigate the impact of gene knockdown on parasite drug susceptibility.

Main Methods:

• Utilized the CRISPR-Cas13 system to target specific mRNA transcripts in Leishmania infantum.
• Quantified knockdown of firefly luciferase, miltefosine transporter (MT), and aquaglyceroporin 1 (AQP1) genes.
• Assessed the functional consequences of knockdown on protein levels, enzyme activity, and drug sensitivity.

Main Results:

• Successfully achieved significant knockdown of exogenous firefly luciferase mRNA, protein, and activity.
• Demonstrated effective knockdown of endogenous MT and AQP1 genes.
• Reduced MT and AQP1 expression correlated with decreased susceptibility to miltefosine and antimonials, respectively.

Conclusions:

• The CRISPR-Cas13 system is a viable tool for targeted gene knockdown in Leishmania.
• This system facilitates functional genomics studies and drug target validation.
• Further optimization holds promise for advancing Leishmania biology research and therapeutic development.